Publications by authors named "K Miskowiak"
Article Synopsis
- Cognitive impairments are common in people with bipolar disorder (BD) even when they are in remission, and traditional cognitive tests can be time-consuming and resource-heavy.
- A study evaluated the Internet-based Cognitive Assessment Tool (ICAT) by having newly diagnosed, remitted BD patients and healthy controls take both traditional and online cognitive tests, showing strong correlations between the two methods.
- The findings suggest that ICAT is a valid and practical option for remote cognitive screening, making it easier to monitor cognitive issues in BD patients.
Article Synopsis
- Accurate diagnosis in psychiatry is challenging, leading to delays in treatment and worse outcomes; identifying biomarkers for emotional reactivity is key.
- The study evaluated emotional responses of individuals with bipolar disorder (BD), borderline personality disorder (BPD), schizophrenia spectrum disorders (SSD), and healthy controls (HC) in immersive virtual reality (VR) scenarios, measuring self-rated emotions and galvanic skin response (GSR).
- Results showed that individuals with BD, BPD, and SSD had more negative emotional responses than HC, with BPD and SSD experiencing heightened unpleasantness and stronger physiological responses in specific VR contexts, suggesting VR assessments could enhance diagnosis and treatment strategies.
Article Synopsis
- Neurofibromatosis type 1 (NF1) is a genetic disorder that can cause various health issues, including cognitive impairments, which are not well-studied in adults; this research focused on evaluating these cognitive issues in adults with NF1.* -
- The study involved 103 NF1 adults and 38 control participants, utilizing a range of neurocognitive tests and a self-report questionnaire to analyze various cognitive functions including intelligence, memory, attention, and executive functions.* -
- Results revealed that adults with NF1 experience significant impairments, particularly in areas like intelligence and visual memory, while some cognitive functions remained intact, suggesting a specific pattern of cognitive deficits rather than a widespread impairment.*
Exploring the effects of erythropoietin treatment on cortical thickness and hippocampal volume in patients with mood disorders undergoing electroconvulsive therapy: A randomized, placebo-controlled trial.
J Psychopharmacol
November 2024
Background: Electroconvulsive therapy (ECT) is a highly effective treatment for severe depression. However, its utilization is limited to the most severely ill patients due to stigma, healthcare provider unfamiliarity, and concerns regarding cognitive side effects. Erythropoietin (EPO) is a promising add-on treatment during ECT due to its potential to increase neuroplasticity and cognition.
View Article and Find Full Text PDFIntroduction: Accumulating data support the association between increased inflammation and bipolar disorder (BD), and preliminary data suggest that augmentation with low-dose aspirin (LDA) may protect against the onset and deterioration of BD via anti-inflammatory pathways. The A-bipolar randomised controlled trial (RCT) aims to investigate whether adding LDA to standard treatment improves day-to-day mood instability (MI) in BD.
Methods And Analysis: A two-arm, triple-blind, parallel-group, superiority RCT including 250 patients with newly diagnosed BD treated at the Copenhagen Affective Disorder Clinic, Denmark.